Aug. 13 - Insmed’s big approval, AbbVie’s production push and a rare IPO

AbbVie to build API plant in Illinois as it steps up US production; Vor says drug licensed from RemeGen succeeded in Sjögren’s study; Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

View online | Signup

Daily Dive

Aug. 13, 2025 | Today’s news and insights for biopharma leaders

BROUGHT TO YOU BY — Fidelity Investments

Give your equity program an edge

As your business grows, Fidelity is there to help with equity management solutions to meet your needs, from startup to IPO and beyond. Put our experience to work.

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.

AbbVie to build API plant in Illinois as it steps up US production

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.

Get your brand in front of biotech & pharma execs

Tell your brand’s story. Secure prime ad placements. Generate qualified leads. Reach your marketing goals with BioPharma Dive’s audience of over 389,000 decision makers. Learn more.

UPDATED

Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

Nasus Pharma on Wednesday became only the third biotech to go public since early May. All three raised $20 million or less.

GSK's Strategic Shift: Unlocking Drug Success

GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.

Watch Now

From Our Library

Trendline